Tag: Selective MAGL inhibitor (second-generation)

  • KML29

    Selective MAGL inhibitor (second-generation)

    A second-generation covalent MAGL inhibitor with improved selectivity over FAAH.

    Abstract

    KML29 (CAS 1366507-82-3; molecular formula C27H24F4N2O4; molecular weight 516.49) is a second-generation covalent MAGL inhibitor developed by Cravatt and colleagues. The compound has improved selectivity for MAGL over FAAH (greater than 4000-fold) compared to JZL184 (300-fold), reducing the off-target FAAH inhibition that complicated interpretation of some JZL184 studies. Mechanism is the same as JZL184: irreversible carbamoylation of MAGL’s active-site serine. Used in academic research where clean MAGL inhibition without FAAH crossover is required. No human clinical development.

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.